LSL Pharma Group Engages Paradox as Investor Relations Services Provider
LSL Pharma Group Engages Paradox as Investor Relations Services Provider
LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and distribution of high-quality natural health products and dietary supplements in solid dosage forms, as well as high quality sterile ophthalmic pharmaceutical products. For more information, please visit and .BOUCHERVILLE, Québec, Oct. 06, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL) – (the "Company" or "LSL Pharma Group"), a Canadian integrated pharmaceutical company, is pleased to announce that it has retained on October 5, 2023 the services of Paradox Public Relations Inc. ("Paradox") to provide investor relations services on behalf of the Company. Paradox is a Montréal-based investor relations consultancy firm that has been in business for over 20 years. Paradox will focus on developing and expanding the Company's communications and visibility with the investment community through a comprehensive investor relations program.
鲍切维尔，QuéBEC，2023年10月6日(环球通讯社)-LSL制药集团有限公司(多伦多证券交易所股票代码：LSL)-(The“The”)公司“或”LSL医药集团加拿大综合制药公司)高兴地宣布，它已于2023年10月5日保留了Paradox Public Relationship Inc.(悖论“)代表公司提供投资者关系服务。Paradox是一家总部位于Montréal的投资者关系咨询公司，已有20多年的业务。Paradox将专注于通过全面的投资者关系计划发展和扩大公司与投资界的沟通和知名度。
The Investor Relations Agreement has a term of 12 months and can be terminated at any time without charge by either party by giving 30 days' notice in writing. Paradox will be paid a monthly fee of $10,000, plus applicable taxes, and are granted stock options to acquire up to 300,000 Class A shares of the Company at a price of $0,70 per share, which options shall be for a period of 10 years and vest in four equal tranches, quarterly over a twelve (12) months period, the whole in accordance with the current stock option plan of the Company and Policy 3.4 of the TSXV. The Investor Relations Agreement as well as the professional engagement fees and granting of the stock options remains subject to TSX Venture Exchange approval.
投资者关系协议的有效期为12个月，任何一方均可随时给予30天书面通知而不收取任何费用而终止。Paradox将获得每月10,000美元的费用，外加适用的税款，并被授予以每股0，70美元的价格收购最多300,000股本公司A类股票的股票期权，这些期权的期限为10年，分四个等量部分，在十二(12)个月期间按季度授予，全部根据本公司当前的股票期权计划和TSXV的第3.4号政策。投资者关系协议以及专业聘用费和授予股票期权仍有待多伦多证券交易所创业板交易所的批准。
ABOUT LSL PHARMA GROUP INC.
约 LSL制药 集团公司
LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and distribution of high-quality natural health products and dietary supplements in solid dosage forms, as well as high quality sterile ophthalmic pharmaceutical products. For more information, please visit and .
LSL Pharma Group是一家加拿大综合性制药公司，专门开发、制造和分销高质量的天然保健品和固体剂型的膳食补充剂，以及高质量的无菌眼科药品。有关更多信息，请访问和。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
都不是这个多伦多证券交易所 风险投资 交易所 也不是 它的 监管 服务 提供商 (作为 那 术语 是 已定义 在……里面 中国的政策 这个 多伦多证券交易所风险投资公司 交易所) 承担责任 为 充分性或 精确度 的 这放手。
CONTACT:
François Roberge, President and Chief Executive Officer
Telephone: 514-664-7700
Email: Investors@groupelslpharma.com
联系方式：
FrçOis Roberge、总裁和首席执行官
电话：514-664-7700
电子邮件：Investors@groupelslpharma.com